Subcutaneous Secukinumab 150 Mg Provides Sustained Relief in Total and Nocturnal Back Pain, Morning Stiffness, Fatigue, and Low Disease Activity in Patients with Active Ankylosing Spondylitis: End-of-study (5-year) Data from the MEASURE 2 Trial

被引：0

作者：

Marzo-Ortega, Helena ^{[1
]}

Miceli-Richard, Corinne ^{[2
]}

Gill, Sonja ^{[3
]}

Magrey, Marina ^{[4
]}

Machado, Paula ^{[5
]}

Shete, Abhijit ^{[6
]}

Wang, Jianyuan ^{[6
]}

Rohrer, Susanne ^{[6
]}

Deodhar, Atul ^{[7
]}

机构：

[1] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, NIHR Leeds Biomed Res Ctr, Leeds Teaching Hosp Trust, Leeds, W Yorkshire, England

[2] Paris Descartes Univ, Hop Cochin, AP HP, Dept Rheumatol, Paris, France

[3] 412 3075 Hosp Gate, Oakville, ON, Canada

[4] Case Western Reserve Univ, Sch Med, Cleveland, OH USA

[5] Novartis Pharmaceut, E Hanover, NJ USA

[6] Novartis Pharma AG, Basel, Switzerland

[7] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2020年 / 72卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0364

引用

页数：3

共 18 条

[11] MEASURE 2: SECUKINUMAB PROVIDES RAPID AND SUSTAINED RELIEF FROM KEY CLINICAL SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS IN TNFI-NAIVE PATIENTS THROUGH 5 YEARS
Pavelka, K.
Kivitz, A.
Calheiros, R.
Quebe-Fehling, E.
Pertel, P.
Blanco, R.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 770 - 771
[12] . SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL WITH SUBCUTANEOUS LOADING AND MAINTENANCE DOSING (MEASURE 2)
Marzo-Ortega, Helena
Sieper, Joachim
Kivitz, Alan
Blanco, Ricardo
Cohen, Martin
RHEUMATOLOGY, 2017, 56 : 94 - 94
[13] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL WITH SUBCUTANEOUS LOADING AND MAINTENANCE DOSING (MEASURE 2)
Marzo-Ortega, H.
Legerton, C. W.
Sieper, J.
Kivitz, A.
Blanco, R.
Cohen, M.
Zuazo, J.
Readie, A.
Porter, B.
Richards, H.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 812 - 813
[14] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL WITH SUBCUTANEOUS LOADING AND MAINTENANCE DOSING (MEASURE-2)
Marzo-Ortega, H.
Legerton, C. W.
Sieper, J.
Kivitz, A.
Blanco, R.
Cohen, M.
Martin, R.
Readie, A.
Richards, H.
Porter, B.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : 783 - 783
[15] Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study
Mease, Philip J.
Landewe, Robert
Rahman, Proton
Tahir, Hasan
Singhal, Atul
Boettcher, Elke
Navarra, Sandra
Readie, Aimee
Mpofu, Shephard
Delicha, Eumorphia Maria
Pricop, Luminita
van der Heijde, Desiree
RMD OPEN, 2021, 7 (02):
[16] SECUKINUMAB IMPROVES MULTIPLE PARAMETERS OF DISEASE ACTIVITY IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS THROUGH 52 WEEKS OF SUBCUTANEOUS THERAPY: DATA FROM THE PHASE 3 MEASURE 2 STUDY
Braun, J.
Sieper, J.
Aelion, J.
Emery, P.
Deodhar, A.
Porter, B.
Andersson, M.
Richards, H.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1147 - 1147
[17] Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study
Deodhar, A.
Conaghan, P. G.
Kvien, T. K.
Strand, V.
Sherif, B.
Porter, B.
Jugl, S. M.
Gandhi, K. K.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (02) : 260 - 269
[18] INTRAVENOUS LOADING AND SUBCUTANEOUS MAINTENANCE WITH SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENT IN MULTIPLE MEASURES OF DISEASE ACTIVITY IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 52-WEEK DATA FROM THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 MEASURE 1 STUDY
Wei, J. C. C.
Baeten, D. L.
Geusens, P.
Porter, B.
Martin, R.
Richards, H.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1146 - 1147

← 1 2 →